CM082, a novel angiogenesis inhibitor, enhances the antitumor activity of gefitinib on epidermal growth factor receptor mutant non-small cell lung cancer in vitro and in vivo.
Kun ZhangLili WangAili WeiXinfei JiaXiaoqing LiuPublished in: Thoracic cancer (2020)
Significant findings of the study CM082, a novel angiogenesis inhibitor, enhances the antitumor activity of gefitinib on EGFR mutant NSCLC by inhibiting proliferation and angiogenesis and promoting apoptosis of tumor cells. What this study adds These findings justify evaluation of the efficacy of CM082 combined with gefitinib in patients with EGFR mutant advanced NSCLC in clinical trials.
Keyphrases
- epidermal growth factor receptor
- small cell lung cancer
- advanced non small cell lung cancer
- tyrosine kinase
- clinical trial
- endothelial cells
- signaling pathway
- vascular endothelial growth factor
- brain metastases
- oxidative stress
- wild type
- endoplasmic reticulum stress
- randomized controlled trial
- wound healing
- cell cycle arrest